Memantine

Generic Name
Memantine
Brand Names
Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
Drug Type
Small Molecule
Chemical Formula
C12H21N
CAS Number
19982-08-2
Unique Ingredient Identifier
W8O17SJF3T
Background

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease .

In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 . In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 .

Indication

Memantine is used to manage moderate to severe Alzheimer's dementia .

A more recent systemic review and meta-analysis indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer's dementia. Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia .

Associated Conditions
Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
Associated Therapies
-

Psychopharmacotherapy in Multiple Substances Abuse

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-08-26
Last Posted Date
2013-02-28
Lead Sponsor
National Cheng-Kung University Hospital
Target Recruit Count
200
Registration Number
NCT01189214
Locations
🇨🇳

Ru-Band Lu, Tainan, Taiwan

Series Studies of Bipolar Disorder-Valproate add-on Memantine

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-08-25
Last Posted Date
2013-09-17
Lead Sponsor
National Cheng-Kung University Hospital
Target Recruit Count
219
Registration Number
NCT01188148
Locations
🇨🇳

Ru-Band Lu, Tainan, Taiwan

Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-04-28
Last Posted Date
2013-02-01
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
42
Registration Number
NCT01112683
Locations
🇺🇸

The Children's Hospital, Aurora, Colorado, United States

Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease

First Posted Date
2010-04-21
Last Posted Date
2012-03-26
Lead Sponsor
University Hospital, Lille
Target Recruit Count
28
Registration Number
NCT01108029
Locations
🇫🇷

Devos, Lille, France

Memantine in Adult Autism Spectrum Disorder

First Posted Date
2010-03-02
Last Posted Date
2017-07-26
Lead Sponsor
Johns Hopkins University
Target Recruit Count
4
Registration Number
NCT01078844
Locations
🇺🇸

Johns Hopkins Bayview, Baltimore, Maryland, United States

Study on Cognitive Disorders of Multiple Sclerosis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-02-24
Last Posted Date
2012-09-03
Lead Sponsor
University Hospital, Caen
Target Recruit Count
90
Registration Number
NCT01074619
Locations
🇫🇷

CHU Caen, Caen, France

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2010-01-22
Last Posted Date
2017-07-11
Lead Sponsor
American Academy of Neurology
Target Recruit Count
29
Registration Number
NCT01054599
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Newton-Wellesley Hospital, Newton, Massachusetts, United States

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-01-20
Last Posted Date
2015-04-01
Lead Sponsor
University of Massachusetts, Worcester
Target Recruit Count
87
Registration Number
NCT01052662
Locations
🇺🇸

University of Massachusetts Medical School, Worcester, Massachusetts, United States

Memantine for Post-Operative Pain Control

First Posted Date
2009-12-31
Last Posted Date
2010-06-29
Lead Sponsor
University of Washington
Target Recruit Count
120
Registration Number
NCT01041313
Locations
🇺🇸

University of Washington Medical Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath